5-Amino-1MQ (50mg)

What is 5-Amino-1MQ Peptide?

5-Amino-1MQ is a cell-permeable, selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in metabolic regulation. By blocking NNMT, it helps preserve nicotinamide for NAD+ synthesis, potentially activating SIRT1 pathways linked to energy balance and fat oxidation.

As an investigational compound, 5-Amino-1MQ is not approved for therapeutic use and is supplied strictly for research purposes into metabolic efficiency, fat metabolism, and cellular energy homeostasis.

5-Amino-1MQ Peptide Description and Research Overview

This quinolinium-based molecule targets NNMT, which methylates nicotinamide using SAM as a donor. In metabolic dysfunction states, NNMT overexpression in fat tissue depletes nicotinamide and lowers NAD+ availability. Inhibition may redirect nicotinamide toward NAD+ production, supporting mitochondrial function and SIRT1 activity.

Preclinical models show protection against diet-induced weight gain, improved body composition, and enhanced metabolic parameters without reducing food intake. Some studies also indicate synergy with exercise, including better grip strength in aged subjects.

Research protocols often use subcutaneous delivery once or twice daily. For lab use, reconstitute the 50 mg vial with 4.0 mL bacteriostatic water for ~12.5 mg/mL (1 unit ≈ 125 mcg on U-100 syringes). Typical ranges are 2.5–5 mg daily, with tolerance assessment at lower doses.

Freeze dry vials at −20 °C; refrigerate mixed solutions at 2–8 °C and use within 2–4 weeks.

5-Amino-1MQ in Research

Investigations into NNMT inhibition reveal protection against diet-induced obesity and metabolic disturbances, with reduced fat accumulation and preserved muscle in animal models. Combined with calorie restriction, it normalizes microbiome profiles in obese subjects.

In aging research, NNMT blockade synergizes with physical activity to improve strength and cellular health. Pharmacokinetic studies confirm good oral bioavailability and plasma half-life, supporting once- or twice-daily dosing.